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ABSTRACT 
 
Extracellular ATP, signalling through P2 receptors, exerts well-documented effects on bone 
cells, inhibiting mineral deposition by osteoblasts and stimulating the formation and 
resorptive activity of osteoclasts. The aims of this study were to determine the potential 
osteotropic effects of adenosine, the hydrolysis product of ATP, on primary bone cells in 
vitro. We determined the effect of exogenous adenosine on 1) the growth, alkaline 
phosphatase (TNAP) activity and bone-forming ability of osteoblasts derived from the 
calvariae of neonatal rats and mice and the marrow of juvenile rats; 2) the formation and 
resorptive activity of osteoclasts from juvenile mouse marrow. RT-PCR analysis showed 
marked differences in the expression of P1 receptors in osteoblasts from different sources.  
Whilst the A1 and A2B adenosine receptors were expressed by all primary osteoblasts, A2A 
receptor expression was limited to rat bone marrow and mouse calvarial osteoblasts and the 
A3 receptor to rat bone marrow osteoblasts. We found that adenosine had no detectable 
effects on cell growth, TNAP activity or bone formation by rodent osteoblasts in vitro. The 
analogue 2-chloroadenosine, which is hydrolysed more slowly than adenosine, had no 
effects on rat or mouse calvarial osteoblasts but increased TNAP activity and bone formation 
by rat bone marrow osteoblasts by 30-50% at a concentration of 1µM. Osteoclasts were 
found to express the A2A, A2B and A3 receptors; however, neither adenosine (≤100µM), nor 
2-chloroadenosine (≤10µM) had any effect on the formation or resorptive activity of mouse 
osteoclasts in vitro. These results suggest that adenosine, unlike ATP, is not a major 
signalling molecule in bone. 
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INTRODUCTION 
The effects of extracellular purines and pyrimidines on cell surface receptors have been 
extensively studied for over 40 years [1]. ATP and related compounds exert their 
physiological affects via seven P2X ligand-gated ion channel receptors and eight P2Y G-
protein coupled receptors that are expressed in most tissues [2,3]. 
The roles played by P2X and P2Y receptors in regulating the function of bone cells have 
received considerable attention in recent years [4].  Osteoblasts, the bone-forming cells, 
express multiple P2 receptors [5,6], in a differentiation-dependent manner [7,8] and respond 
to extracellular nucleotides with a prompt increase in intracellular calcium [7-10]. Importantly, 
exogenous ATP, UTP and other nucleotide analogues also potently inhibit mineralisation of 
bone formed by osteoblasts in culture [8,11,12]. Moreover, endogenous ATP released by 
osteoblasts also appears to act as a significant local inhibitor of mineralisation [13]. The 
action of UTP, together with data from pharmacological studies using other selective P2 
receptor agonists and antagonists indicated that P2Y2, P2X1 and P2X7 receptors could be 
involved in mediating the inhibition of mineralisation by ATP [8,12,13].  
Osteoclasts, the bone-resorbing cells also express most P2 receptors [14] and respond to 
extracellular nucleotides with elevation of intracellular calcium [15]. Moreover, extracellular 
ATP, ADP and UDP have been shown to increase the formation and resorptive activity of 
primary rodent osteoclasts in vitro [14,16-18]. Pharmacological evidence now suggests that 
the pro-resorptive action of ATP and related molecules are mediated by the P2Y1, P2Y6 and 
P2Y12 receptors [14,17-19]. 
Adenosine is a hydrolysis product of ATP and is formed extracellularly by the actions of 
ecto-nucleotidases. There are four major families of these ecto-enzymes: (1) ecto-
nucleoside triphosphate diphosphohydrolases (NTPdases), which hydrolyse ATP to ADP 
and finally AMP; (2) ecto-nucleotide pyrophosphatase/phosphodiesterases (NPPs) that 
hydrolyse ATP to AMP, with the release of pyrophosphate; (3) alkaline phosphatases, which 
sequentially remove single phosphate groups and can hydrolyse ATP through to adenosine; 
and (4) ecto-5’nucleotidase, that hydrolyses AMP to adenosine. Extracellular adenosine 
concentrations are usually <300nM [20] but can rise to approximately 1μM under conditions 
of physiological stress [21]. 
The physiological actions of adenosine have been studied for over 90 years. Adenosine 
acts via the G-protein coupled P1-receptors, found on the surface of many cell types. The P1 
receptor family can be subdivided into the A1, A2A, A2B and A3 receptors [22]. The A2A and 
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A2B adenosine receptors are predominantly stimulatory and are coupled to Gs to stimulate 
cAMP signalling; the A1 and A3 receptors are mainly Gi coupled and act to inhibit cAMP 
signalling [22]. 
Both osteoblasts and osteoclasts have been reported to express all four P1 receptor 
subtypes [23-27]. However, the actions of extracellular adenosine on bone cells appear to be 
somewhat less clear-cut than those of ATP. Synthetic adenosine analogues caused a 
receptor-mediated rise in cAMP levels in calvarial osteoblast-like cells [28] but adenosine 
had no effect on intracellular calcium levels in these cells [7]. Two independent groups failed 
to find an effect of adenosine on the formation of mineralised bone nodules by rat calvarial 
osteoblasts [11,29]. However, a more recent study indicated that adenosine, acting via the 
A2B receptor, may increase the osteogenic differentiation of rat long bone mesenchymal 
stem cells [24].  In addition, a synthetic A2B receptor agonist has been shown to increase 
bone formation, and bone marrow osteoblasts from A2B receptor knockout mice display 
reduced levels of bone formation [30]. Recently, it has also been reported that stimulation of 
the A2A receptors can enhance bone regeneration [31]. 
The study of Lerner et al (1987) found that adenosine analogues had no effect on the 
resorption of cultured mouse calvarial bones. Adenosine was later shown to be without effect 
on the formation or resorptive activity of primary rodent osteoclasts in vitro [16,17]. 
Adenosine was also reported to have no effect on intracellular calcium levels in rabbit 
osteoclasts in vitro [32].  However, more recent work has indicated that adenosine, acting 
through the A2A receptor, may stimulate the formation of osteoclasts from human peripheral 
blood cells [25]. In contrast, Mediero et al (2012) [33] found that A2A receptor agonists 
inhibited mouse osteoclast formation in vitro. Blockade or deletion of the A1 receptor has 
additionally been reported to reduce the formation of mouse osteoclasts in culture [23]; 
however, the same group also found that stimulation of the A1 receptor had no effect on 
mouse osteoclasts [34].  
The aim of the present study was to determine the direct actions of adenosine on normal 
osteoblasts and osteoclasts, using well-characterised assays that measure the accepted 
physiological functions (i.e. bone formation and bone resorption) of these cells. 
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METHODS 
Reagents 
All tissue culture and molecular biology reagents were purchased from Life Technologies 
(Paisley, UK) unless stated otherwise. Chemical reagents were purchased from Sigma 
Aldrich (Poole, UK). 2-chloroadenosine, GR79236, BAY606583, CGS15943 and pentostatin 
were purchased from Tocris (Bristol, UK). P1 receptor antibodies were obtained from 
Alomone (Jerusalem, Israel), the β-actin antibody from Abcam (Cambridge, UK) and HRP-
conjugated secondary antibodies from Jackson Immunoresearch Laboratories (Philadelphia, 
USA). 
Primary bone cell culture 
This study used osteoblasts from several sources namely rat / mouse calvaria and rat bone 
marrow.  Osteoclasts were obtained from mouse bone marrow.  These methods represent 
the most widely used and well validated methods for obtaining primary bone cells for in vitro 
research. 
Rat / mouse calvarial osteoblasts: primary cells were derived from the calvarial bones of 2-4 
day old rats (Sprague-Dawley) and mice (C57BL/6 or 129/SvTerJ). Osteoblasts were 
obtained using methods similar to those previously described [35-37]. Briefly, calvariae were 
digested using 0.25% trypsin for 10 minutes, 0.2% collagenase in Hank’s buffered salt 
solution (HBSS) for 30 minutes, and finally 0.2% collagenase in HBSS for 60 minutes, all at 
37ºC. The first two digests were discarded and cells from the final digest were resuspended 
in Dulbecco’s modified essential medium supplemented with 10% foetal calf serum, 2mM L-
glutamine, 100U/ml penicillin, 100 μg/ml streptomycin, 0.25 μg/ml amphotericin (mixture 
abbreviated to ‘DMEM’). Due to increased nutritional requirements [36], mouse cells were 
resuspended in α-modified essential medium supplemented with 10% foetal calf serum, 
70μg/ml gentamicin, 50U/ml penicillin, 50 μg/ml streptomycin, 0.125 μg/ml amphotericin 
(mixture abbreviated to ‘α-MEM’).  
Osteoblasts were cultured for 4 days in 75 cm2 flasks in a 5% CO2 atmosphere at 37ºC 
until confluent. Upon confluence, rat cells were then plated into 6-well trays in DMEM further 
supplemented with 2mM β-glycerophosphate, 50μg/ml ascorbate and 10nM dexamethasone 
(mixture abbreviated to ‘supplemented DMEM’) [35-37]. Mouse cells were plated into 6 well 
trays in α-MEM further supplemented with 2mM β-glycerophosphate and 50 μg/ml ascorbate 
(mixture abbreviated to ‘supplemented α-MEM’). Osteoblasts were treated with 1nM–100μM 
adenosine, 2-chloroadenosine, GR79235 (selective A1 receptor agonist), BAY606583 (a 
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selective A2B receptor agonist), CGS15943 (a non-selective P1 receptor antagonist), 
pentostatin (an adenosine deaminase inhibitor), ATP or PBS (vehicle) for the duration of the 
culture. Half-medium changes were performed every third day of culture. Experiments were 
terminated by fixing the cells in 2.5% glutaraldehyde for 5 minutes. Cell culture plates were 
imaged at 800 dpi using a flat-bed scanner (Epson Perfection 4990 Photo) and the total area 
of bone nodules formed was quantified by image analysis, as described previously [35-37].  
Rat bone marrow osteoblasts: Primary rat osteoblasts of bone marrow / stromal cell origin 
were obtained from the long bones of 6-week old Sprague-Dawley rats. The epiphyses were 
cut across and the marrow was flushed out of the bones using PBS. The collected cells were 
suspended in α-MEM and pre-cultured in a 75 cm2 flask in 5% CO2 at 37ºC. After 24 hours 
all the α-MEM was replaced in order to eliminate non-adherent cells; adherent stromal cells 
were cultured for a further 2 days until confluent. Upon confluence, cells were plated into 6-
well trays and cultured as described above.   
Mouse osteoclasts: Osteoclasts were formed from precursors flushed from the bone marrow 
of 8-week old mice using previously described methods [38]. Cells were pre-incubated in a 
75 cm2 flask containing modified essential medium supplemented with 10% FCS, 2mM L-
glutamine, 100U/ml penicillin, 100μg/ml streptomycin, 0.25μg/ml amphotericin and 100nM 
prostaglandin E2 (abbreviated as ‘MEM’), supplemented with 2.5ng/ml macrophage colony 
stimulating factor (M-CSF; R&D Abingdon, UK) in 5% CO2 at 37ºC. After 24 hours the non-
adherent mononuclear cells remaining in the culture medium were collected. The cells were 
re-suspended in MEM supplemented with 10ng/ml M-CSF and 3ng/ml receptor activator of 
NF-κB (RANKL) (R&D Abingdon, UK) and seeded onto 5 mm-diameter ivory discs in a 96 
well tray (106 cells/disc). After a further 24 hours the ivory discs were transferred into 6-well 
trays and cultured for 6 days at pH 7.30. Discs were cultured for the final 2 days in medium 
acidified to pH 6.90 to activate osteoclastic resorption [38] before fixation in 2.5% 
glutaraldehyde and staining to demonstrate tartrate-resistant acid phosphatase (TRAP). 
Osteoclasts were identified as TRAP-positive cells with ≥2 nuclei. The numbers of 
osteoclasts and area resorbed per disc were evaluated ‘blind’ using transmitted and 
reflected light microscopy, as described previously [38]. 
Alkaline phosphatase activity 
Osteoblast tissue non-specific alkaline phosphatase (TNAP) activity was measured in cell 
lysates taken defined stages of osteoblast differentiation (proliferating, differentiating, 
mature, mature bone-forming) using a colorimetric kit (Anaspec, CA, USA), as previously 
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described [35]. TNAP activity was normalised to cell protein using the Bradford reagent 
(Sigma-Aldrich, Poole, UK). 
Cell number and viability assays 
Osteoblast cell number was measured at regular intervals throughout the culture period 
using a commercially available kit (CytoTox 96, Promega UK, Southampton, UK), as 
previously described [13]. This assay measures the activity of lactate dehydrogenase (LDH), 
a cytosolic enzyme which is released on cell lysis. 
RNA extraction and RT-PCR 
Osteoblasts were cultured in 6-well trays for up to 28 days and total RNA was extracted 
using TRIzol reagent, according to the manufacturer’s instructions. Osteoclasts were 
cultured on 1cm diameter dentine discs for up to 10 days before RNA extraction. RNA was 
treated with RNase-free DNase I (Promega, Madison, USA) for 30 min at 37°C to remove 
contaminating genomic DNA. The reaction was terminated by heat inactivation at 65°C for 
10 minutes. Total RNA was quantified spectrophotometrically by measuring absorbance at 
260nm. cDNA was synthesised from approximately 1μg of RNA using Superscript III reverse 
transcriptase, oligo dT, RNasin and a deoxyribo-nucleotide mix. 
The cDNA produced from osteoblast and osteoclast RNA was amplified by PCR using 1U 
GoTaq DNA polymerase, 1.5mM MgCl2, 0.8μM nucleotide mix (Promega, Madison, USA) 
and 0.5μM primers (MWG Biotech, Ebersberg, Germany). The primer sequences used for 
rat and mouse RT-PCR are shown in Table 1. 
Western blot 
Protein was extracted from mature rat calvarial osteoblasts and osteoclasts.  Cell layers 
were lysed in ice-cold radio immunoprecipitation (RIPA) lysis buffer (50mM Tris HCl pH 7.4, 
150mM NaCl, 5mM EDTA, 0.1% SDS 1mM phenyl methyl sulfonyl fluoride (PMSF), 1mg/ml 
aprotinin, 1mM Na3VO4 and 2.5mg/ml deoxicolic acid).  Cell homogenates were sonicated 
for 5 min and stored at -80C for at least half an hour before use.  Protein concentrations 
from lysates were determined using the Bradford assay (Sigma Aldrich, Gillingham, Dorset, 
UK).  Prior to loading total protein samples were denatured by incubating at 95C for 5 min 
in the presence of 5x reducing sample buffer (60mM Tris-HCl pH 6.8, 25% glycerol, 2% 
SDS, 10% -mercaptoethanol and 0.1% bromophenol blue).  Protein samples (20g/lane) 
were loaded into SDS-PAGE (10%) gels and transferred onto a polyvinylidenifluoride 
(PVDF) membrane (Amersham, Buckinghamshire, UK) by the use of a wet tank blotter (Bio-
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Rad, Hercules, CA, USA) at 150 V for 1 hour.  Membranes were then blocked with 5% non-
fat milk and incubated with one of the P1 receptor antibodies (1:200) or β-actin (1:1000) 
overnight at room temperature.  After washing, blots were incubated in horseradish 
peroxidase-conjugated secondary antibodies for 1 hour at room temperature (1:10,000).  A 
peroxidase detection system (Immobilon™ Western, Millipore UK, Watford, UK) was used 
for the visualisation of the immunoreactivity.   
Statistics 
Statistical comparisons were made using one-way analysis of variance (ANOVA) and 
adjusted for multiple comparisons using the Bonferroni method. Calculations were performed 
using In Stat 3 (GraphPad, San Diego, CA). All data are presented as means ± SEM for 6 - 
12 biological replicates. Results are representative of experiments performed at least three 
times, using cells from different animals. 
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RESULTS 
Rodent osteoblasts and osteoclasts express P1 receptor mRNA in vitro 
Total RNA was extracted from mature, bone-forming osteoblasts derived from rat calvaria 
(day 14), rat bone marrow (day 17) and mouse calvaria (day 28). RT-PCR showed mRNA 
expression of the A1 and A2B receptors in rat calvarial osteoblasts and all P1 receptors in rat 
bone marrow osteoblasts (Fig. 1A).  Mouse calvarial osteoblasts expressed mRNA for A1, 
A2A and A2B receptors but not the A3 receptor (Fig. 1A).   
 RNA was extracted from mature, resorbing osteoclasts (day 10 of culture) for 
investigation of P1 receptor expression.  Osteoclasts were found to express mRNA for the 
A2A, A2B and A3 receptors (Fig.1A) 
 Total protein was extracted from mature rat calvarial osteoblasts and mouse osteoclasts. 
Western blot analysis revealed expression of A2A and A2B, receptor protein in osteoblasts; A1 
and A3 receptor protein was not detected (Fig. 1B).  Osteoclasts were found to express 
protein for all four adenosine receptors (Fig.1B). 
The effects of P1 receptor agonists on bone formation 
Rodent calvarial osteoblasts and rat bone marrow osteoblasts were cultured for up to 28 
days with adenosine, 2-chloroadenosine and ATP.  Rat calvarial osteoblasts were also 
additionally treated with the more selective agonists, GR79236 (A1) and BAY606583 (A2B).  
Representative light microscopy images of adenosine and 2-chloroadenosine-treated cell 
layers are shown in Fig. 2.   In cultures of calvarial and bone marrow osteoblasts, adenosine 
had no effect on the level of bone formation (Fig. 3A-3C). 2-chloroadenosine was without 
effect in calvarial osteoblasts (Fig. 3D & 3E) but caused a small stimulatory effect at 1μM in 
bone marrow osteoblasts (Fig. 3F). Concentrations of ≥10μM 2-chloroadenosine appeared 
to have toxic effects, resulting in a complete abolition of bone formation. ATP (≥10μM) 
inhibited mineralisation by ≤90% and ≤85% in calvarial and bone marrow osteoblasts, 
respectively (Fig. 3G -3I).  Treatment with GR79236 and BAY606583 also had no effect on 
bone formation by osteoblasts (Fig. 4A & 4B).   
Endogenous adenosine does not affect bone formation 
Rat osteoblasts were cultured with CGS15943, a non-selective P1 receptor antagonist, and 
pentostatin, an adenosine deaminase inhibitor, to determine whether endogenous 
adenosine influences bone formation.  Both CGS15943 and pentostatin (≤1µM) had no 
effect on the level of bone formation (Fig. 4C & 4D). 
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Increased TNAP activity in bone marrow osteoblasts treated with 2-chloroadenosine 
The effect of adenosine and 2-chloroadenosine on TNAP activity was measured in calvarial 
and long bone osteoblasts at different stages of differentiation (proliferating, differentiating, 
mature, mature-bone forming). Adenosine had no effect on TNAP activity (Fig. 5A, 5B, 5C). 
2-chloroadenosine (1μM) was without effect in calvarial osteoblasts (Fig. 5D, 5E) but 
increased TNAP activity by ≤48% in rat bone marrow osteoblasts (Fig. 5F). This effect was 
evident in differentiating (day 11), mature (day 14) and mature, bone forming (day 17) 
osteoblasts. 
Osteoblast numbers are unaffected by adenosine or 2-chloroadenosine 
Calvarial and long bone marrow osteoblasts were cultured for up to 28 days with adenosine 
or 2-chloroadenosine; cell numbers were estimated at the different stages of osteoblast 
differentiation using a lactate dehydrogenase assay.  Adenosine had no effect on calvarial or 
long bone osteoblast numbers at any time point at concentrations up to 100μM (Fig. 6A-C).   
2-chloroadenosine did not influence cell number in cultures of rat calvarial osteoblasts at 
concentrations up to 10μM (Fig. 6D).  In mouse calvarial and rat long bone osteoblasts, 
≤1μM 2-chloroadenosine had no effect on cell number but 10μM 2-chloroadenosine was 
toxic, resulting in widespread cell death (Fig. 6E & 6F). 
Lack of effect of adenosine or 2-chloroadenosine on osteoclast formation and 
resorptive activity 
The effect of adenosine, 2-chloroadenosine and ATP was examined in cultures of mouse 
osteoclasts cultured on ivory discs. Representative light microscopy images of treated 
osteoclasts are shown in Fig. 7A.  At all the concentrations tested, adenosine (Fig. 7B, 7E) 
and 2-chloroadenosine (Fig. 7C, 7F) had no effect on osteoclast number or the amount of 
resorption per osteoclast. In contrast, ATP increased osteoclast formation up ≤75% and 
bone resorption by up to 2-fold (Fig. 7D, 7G). 
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DISCUSSION 
The role of adenosine in the regulation of bone cell function has been a significant area of 
study (see review [39]) yet published data presents conflicting results. The aim of this 
investigation was to clarify the functional effects of adenosine on osteoblasts and 
osteoclasts. We found that adenosine and the selective P1 receptor agonists, GR79236 (A1) 
and BAY606583 (A2B), had no effect on osteoblast number and / or bone formation. 
However, 2-chloroadenosine (a synthetic, universal P1 receptor agonist) modestly increased 
TNAP activity and bone formation by rat bone marrow osteoblasts, but did not affect rat and 
mouse calvarial osteoblasts. Osteoclast formation and activity was also unaffected by 
adenosine or 2-chloroadenosine. In contrast, the established osteogenic inhibitory effects 
[12] and osteoclastic stimulatory effects [17] of ATP were readily observed in all cells. 
The work presented here showed no effects of adenosine, 2-chloroadenosine, GR79236 
or BAY606583 on calvarial-derived osteoblasts; this is in broad agreement with previous 
studies which showed exogenous adenosine had no effect on cultured rat osteoblasts 
[11,29]. However, our results are at variance with several studies which found that 
adenosine or adenosine analogues, acting via the A2A or A2B receptors, stimulate the 
differentiation and function of human and rodent bone marrow osteoblasts and promote 
bone regeneration [24,30,31,40].  Our data also do not concur with the reported inhibitory 
effects of adenosine analogues, acting via A1 or A2A receptors, on the differentiation of rodent 
osteoblast-like cells [41] or human osteoblasts [40].  We did observe small stimulatory 
effects of 2-chloroadenosine on rat bone marrow osteoblasts. This synthetic agonist is more 
potent than adenosine and is hydrolysed more slowly [42]. Differences in agonist 
pharmacology may therefore explain why we observed small effects with this analogue but 
adenosine was inactive in bone marrow osteoblasts.  
It is possible that significant differences in osteoblast culture methodologies also 
contributed to the divergent results between studies. Bone formation in vitro can be 
influenced by a number of variables including use of glucocorticoids (which are strongly 
osteogenic for rat but not mouse-derived cells in vitro [36,43] in the culture medium, culture 
duration, cell seeding densities, tissue culture medium, β-glycerophosphate concentration 
and the age of the animals from which the cells were isolated.  
The breakdown of ATP released by cells represents a key source of extracellular 
adenosine. Osteoblasts release ATP constitutively [44,45] and can generate low micromolar 
concentrations of adenosine in vitro [21,27].  Therefore, the possibility remains that 
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endogenous adenosine exerts effects on osteoblasts that are not enhanced further by the 
addition of exogenous adenosine.  To investigate this possibility further, rat osteoblasts were 
cultured with a non-selective P1 receptor antagonist, CGS15943, to block all adenosine-
mediated signalling.   Cells were also cultured with pentostatin which inhibits adenosine 
deaminase and prevents adenosine breakdown to inosine.  Both CGS15943 and pentostatin 
had no effect on the level of bone formation in vitro.  Taken together, this suggests that 
signalling mediated by endogenous adenosine does not exert a significant effect on calvarial 
osteoblast function.  
Earlier work has shown that osteoblasts express all the adenosine receptors [24,27].  The 
present study examined the expression profile of P1 receptors in mature, bone forming 
osteoblasts from different sources.  In agreement with the previous studies, rat bone marrow 
expressed low levels of mRNA for all four receptors.  However, calvarial osteoblasts 
displayed more restricted expression at both the protein and mRNA level.  Osteoblasts 
expressed mRNA for the A1 receptor yet no protein was detected, suggesting this receptor is 
not translated.  In contrast, we found that osteoblasts expressed A2A receptor protein but not 
mRNA.  This discrepancy suggests that expression of A2A receptor mRNA is below the 
threshold that can be detected by conventional PCR. The limited adenosine receptor 
expression on calvarial osteoblasts may also contribute to the lack of functional effects seen 
in these cells.  
Previous work reported that P1 receptor expression by human and rat bone marrow 
mesenchymal stem cells and osteoblasts is strongly dependent on differentiation [40,24], as 
is P2 receptor expression by rat calvarial osteoblasts [7]. Although not investigated here, it is 
possible that P1 receptor expression in osteoblasts is also affected by differentiation.   
Several studies have shown that A1 receptors and A2A receptors can form homomers 
[46,47] or A1-A2A heteromers [48]. A1-P2Y1 and A1-P2Y2 adenosine-receptor-ATP-receptor 
G-protein heteromers have also been reported [49,50]. This receptor dimerisation may lead 
to alterations in downstream signalling and cellular responses to P1 receptor agonists, 
potentially contributing to the different effects observed between cell types.  
Available data regarding the effects of adenosine and P1 receptors on osteoclasts are 
also conflicting. Consistent with earlier studies we show that osteoclasts express all four 
adenosine receptors, albeit at a low level [23,25].  However, we demonstrate that adenosine 
has no effect on the formation or resorptive activity of mouse osteoclasts grown on dentine. 
These results are in agreement with some previous investigations [16,17] but differ from 
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others. For example, A2A receptor agonists have been shown to both inhibit [33] and 
stimulate [25] the formation and activity of osteoclasts. Kara and colleagues [51] found that 
A1 receptor antagonists decreased osteoclast formation and resorption. However, we found 
that mouse osteoclasts only express low levels of A1 receptor protein. Pellegatti et al [25] 
also reported that the A1 receptor was only weakly expressed by osteoclasts formed from 
human peripheral blood. Taken together, this suggests that the A1 receptor is unlikely to play 
a role in regulating osteoclast function. It should be noted that the culture conditions used by 
the above studies varied considerably. Osteoclast formation and activity is strongly 
influenced by factors including RANKL/M-CSF concentration, substrate (dentine, bone or 
plastic), pH, source of cells and culture duration [38]. Thus, different experimental conditions 
combined with variations in P1 receptor expression may account for the disparity between 
studies. 
The lack of effect of adenosine on osteoblasts and osteoclasts in this study suggests that 
the P1 receptors are not critical in regulating bone cell function directly. However, A1 and A2B 
receptor knockout mice are reported to display increases in the trabecular and/or cortical 
bone [23,30], whilst A2A receptor knockout mice have decreased cortical and trabecular bone 
[33]. At present, the A3 receptor knockout has not been investigated for specific changes in 
the bone; however, no overt changes in phenotype have been noted [52]. Adenosine 
receptors display widespread expression and are involved in many biological processes 
including coronary vasodilation [53], VEGF production, angiogenesis [54,55] and nerve 
transmission [56]. Thus it is possible that the changes in bone mass seen in the knockout 
mouse models are occurring indirectly via actions on other tissues.  
This study used established and well validated assays for measuring accepted bone cell 
function. We clearly show that supraphysiological concentrations of adenosine did not affect 
rodent osteoblasts or mouse osteoclasts. In rat bone marrow osteoblasts, 2-chloroadenosine 
exerted small effects on TNAP activity and bone formation, but only when added to cell 
cultures in extremely high concentrations. 2-chloroadenosine was without effect on the other 
cell types used. We also provide evidence to suggest endogenous adenosine does not 
influence bone formation. Taken together these data suggests that adenosine has very little 
direct effect on osteoblast and osteoclast function. 
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Table 1 
Primer sequences used for RT-PCR analysis of rodent P1 receptor mRNA expression. 
GAPDH = glyceraldehyde-3-phosphate dehydrogenase 
 
Rat primer 5’ – 3’ Sense Anti-sense 
A1 receptor CTCCATTCTGGCTCTGCTCG CTCCATTCTGGCTCTGCTCG 
A2A receptor CCATGCTGGGCTGGAACA GAAGGGGCAGTAACACGAACG 
A2B receptor TGGCGCTGGAGCTGGTTA GCAAAGGGGATGGCGAAG 
A3 receptor AGAGCTAGGTCCACTGGC GCACATGACAACCAGGGGGATGA 
β-actin GTTCGCCATGGATGACGAT TCTGGGTCATCTTTTCACGG 
Mouse primer 5’ – 3’ Sense Anti-sense 
A1 receptor CTACCTTCTGCTTCATCGTA ACAAGACAGTGGTGACTCAG 
A2A receptor CTATTGCCATCGACAGATAC GAACAACTGCAGTCAGAAAG 
A2B receptor CCACCAACTACTTTCTGGTA AACAGTAAAGACAGTGCCAC 
A3 receptor TCATTGTCTCCCTAGCACT GACARCRRCRACARCARCCG 
GAPDH CTCACTCAAGATTGTCAGCA GTCATCATACTTGGCAGGTT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
15 
 
FIGURE LEGENDS 
Figure 1. Expression of P1 receptors by rodent bone cells 
(A) Rat calvarial osteoblasts express A1 and A2B receptor mRNA whilst rat bone marrow 
osteoblasts showed expression of all four adenosine receptors.  Mouse calvarial osteoblasts 
express the A1, A2A and A2B receptors.  Mouse osteoclasts expressed mRNA for the A2A, A2B 
and A3 receptors.  Positive control: rat/mouse brain. (B) Western blot analysis shows that rat 
calvarial osteoblasts express low levels of A2A and A2B receptor protein.  Mouse osteoclasts 
express protein for all four of the adenosine receptors.  Images are representative of 
experiments performed using mRNA and protein from three separate cell populations. 
Figure 2.   Effects of adenosine and 2-chloroadenosine on mineralised bone nodule 
formation by rodent osteoblasts 
Representative images (n=5) showing alizarin red-stained mineralised bone nodules, viewed 
by phase contrast microscopy (left) and low power reflected light scans (right).   Adenosine 
( 100µM) had no effect on bone formation by rat calvarial, mouse calvarial or rat bone 
marrow osteoblasts (cultured on plastic for 14, 28 and 17 days, respectively).   2-
chloroadenosine (1µM) caused a modest increase in bone formation by rat bone marrow 
osteoblasts only. Scale bars:  left, 1mm; right, 1cm. 
Figure 3.  Effects of adenosine, 2-chloroadenosine and ATP on mineralised bone 
nodule formation by cultured rodent osteoblasts 
Adenosine had no effect on mineralised nodule formation in cultures of (A) rat calvarial, (B) 
mouse calvarial or (C) rat bone marrow osteoblasts.  2-chloroadenosine was also without 
effect in (D) rat calvarial or (E) mouse calvarial osteoblasts but caused (F) a ~50% increase 
in nodule formation by rat bone marrow osteoblasts (1µM only).  The complete abolition of 
bone formation at concentrations of (E, F) 10µM and (D) 100µM 2-chloroadenosine suggests 
toxicity at these levels.  ATP inhibited bone formation by (G) rat calvarial, (H) mouse 
calvarial and (I) rat bone marrow osteoblasts by up to 90%.   Data are means  SEM for 6 
replicate determinations, n=5; * = p <0.05; ** = p <0.01; *** = p <0.001. 
Figure 4.  The effects of selective adenosine receptor agonists and endogenous 
adenosine on bone formation by osteoblasts 
At concentrations up to 10µM the selective (A) A1 agonist, GR79236, and (B) A2B agonist, 
BAY606583 did not affect mineralised bone nodule formation by rat calvarial osteoblasts. (C) 
The non-selective adenosine receptor antagonist, CG15943, and (D) the adenosine 
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deaminase inhibitor, pentostatin, also had no effect on the level of bone formation. Data are 
means  SEM for 6 replicate determinations (n=3).  
Figure 5.  Effects of adenosine and 2-chloroadenosine on alkaline phosphatase 
(TNAP) activity of rodent osteoblasts 
Culture with adenosine had no effect on TNAP activity in (A) rat calvarial, (B) mouse 
calvarial and (C) rat bone marrow osteoblasts at any stage of culture.  2-chloroadenosine 
had no effect on TNAP activity in (D) rat and (E) mouse calvarial osteoblasts but (F) 
increased TNAP activity by up to 48% in rat bone marrow osteoblasts. Data are means  
SEM for 6 replicate determinations (n=3-5): * = p<0.05, ** = p<0.01. 
Figure 6.   Osteoblast number is unaffected by adenosine and 2-chloroadenosine 
Treatment with adenosine had no effect on cell number in cultures of (A) rat calvarial, (B) 
mouse calvarial and (C) rat bone marrow osteoblasts at any stage.  2-chloroadenosine 
(≤1µM) was also without effect in D) rat calvarial, (E) mouse calvarial and (F) bone marrow 
osteoblasts.  [0] indicates that there were no viable cells present suggesting toxicity at 
concentrations of ≥10µM 2-chloroadenosine. Data are means  SEM for 6 replicate 
determinations (n=3-5). 
Figure 7. Lack of effect of adenosine and 2-chloroadenosine on the formation and 
resorptive activity of mouse osteoclasts 
Osteoclasts were generated in 10 day cultures of mouse marrow cells on ivory discs, in the 
presence or absence of adenosine, 2-chloroadenosine or ATP.  Cells were acidified to pH 
6.90 on day 8 of culture to activate resorption.   (A) Representative transmitted light images 
of cultures, showing tartrate-resistant acid phosphatase-positive multinucleated osteoclasts 
(large red cells) and resorption pits (tan areas); scale bar = 50 µm.   (B, E) Adenosine and 
(C, F) 2-chloroadenosine were without effect on osteoclast formation and resorptive activity.  
(D, G) ATP increased osteoclast formation by 75% and resorption by 2-fold.   Data are 
means  SEM for 8 replicate determinations (n=3); * = p<0.05; ** = p<0.01; ** = p<0.001.  
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